 Daptomycin, a cyclic lipopeptide antibacterial agent, shows rapid in vitro bactericidal activity with concentration-dependent killing for Gram-positive organisms, including S. aureus. Surveillance studies have demonstrated a daptomycin MIC90 of 0.5μgml for both methicillin-susceptible S. aureus MSSA and MRSA with 99 of MRSA isolates being categorized as susceptible by the Food and Drug Administration FDA, European Committee of antimicrobial susceptibility testing EUCAST and Clinical and Laboratory Standards Institute CLSI breakpoints 5. Clinical trials in adults demonstrated that daptomycin was safe and efficacious in complicated skin and skin structure infections cSSSI and bloodstream infections caused by S. aureus, including right-sided infective endocarditis RIE. However, information on the safety and efficacy of daptomycin for use in children is lacking. 